Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

ACAD - Acadia Pharmaceuticals to Host R&D Day in New York City on June 25 2025


home / stock / acad / acad news

RSS
ACAD ACAD Quote ACAD Short ACAD News ACAD Articles ACAD Message Board
  • June, 05 2025 09:05 AM
  • |
  • Business Wire

MWN AI Summary *

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced that it will host a Research and Development (R&D) Day in New York City on June 25, 2025, starting at 8:30 AM ET. This event aims to spotlight the company's ongoing clinical advancements in neurological and rare diseases. Attendees will hear from Acadia's management team, the R&D organization, alongside key opinion leaders (KOLs) and representatives from the caregiver community. This forum will provide valuable insights into Acadia's innovative pipeline and strategic focus within the neuroscience domain.

Acadia Pharmaceuticals has been a leader in pioneering treatments that address critical neurological disorders. The company is recognized for developing the first and only FDA-approved medication for treating hallucinations and delusions related to Parkinson’s disease psychosis. Additionally, it has produced the only approved drug in the U.S. and Canada for Rett syndrome. Acadia’s commitment to advancing neurological health is evident in its clinical development programs, which are currently targeting conditions such as Prader-Willi syndrome, Alzheimer’s disease psychosis, and other neuro-rare diseases.

For those interested in participating, a live webcast of the R&D Day will be available for registration, and a replay will be hosted on Acadia's website for approximately three months following the event. For further information, interested parties are encouraged to visit Acadia's website and follow the company on LinkedIn and X to stay updated on the latest developments and initiatives.

For additional details, investor inquiries can be directed to Acadia's investor relations team, while media-related questions can be addressed through their dedicated media contact.

MWN AI Analysis *

As Acadia Pharmaceuticals Inc. prepares to host its R&D Day in New York City on June 25, 2025, investors should closely monitor the event as a critical opportunity for insights into its ongoing projects and strategic direction. Acadia has carved a niche in the neuroscience domain, highlighted by its pioneering work with medications for Parkinson’s disease psychosis and Rett syndrome. This R&D day is expected to showcase not only the company’s current offerings but also its robust pipeline targeting high-needs areas such as Prader-Willi syndrome and Alzheimer’s disease psychosis.

Investors should pay special attention to the discussions featuring key opinion leaders (KOLs) and caregivers, as these perspectives can provide valuable insights into the efficacy and societal integration of Acadia’s treatments. The focus on both neurological and rare diseases reflects a strategic approach that could enhance market potential and generate partnerships or collaborations that drive future growth.

It is also essential that investors examine the company’s financial model and how its R&D expenditures align with projected revenue streams from these medications, particularly given the challenges in drug approval and market access in the healthcare landscape. Assessing how Acadia communicates its roadmap can offer clarity on execution risks and investment timelines.

Considering Acadia’s track record of bringing meaningful therapies to market, the upcoming R&D day could serve as a pivotal moment for gauging investor confidence. Should the management team provide strong updates on clinical trial results or regulatory progress, it could positively impact share performance. Conversely, any setbacks or delays could have the opposite effect.

In summary, Acadia Pharmaceuticals presents an intriguing investment case, contingent upon the successful elucidation of its strategic pipeline and market position during the R&D Day. Investors are advised to maintain a watchful eye on developments and remain agile in responding to market dynamics post-event.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.


Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June 25, 2025 at 8:30 AM ET.

The event will feature members of Acadia’s management team and R&D organization, key opinion leaders (KOL) and members of the caregiver community.

To register for the live webcast, please click here. A replay of Acadia’s R&D Day will be available on the company’s website, acadia.com , under the investors section for approximately 3 months following the event.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at acadia.com and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250604630277/en/

Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com

Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com


MWN AI FAQ **

What specific advancements in the neurological and rare diseases pipeline will be highlighted during the R&D Day hosted by ACADIA Pharmaceuticals Inc. (ACAD) on June 25, 2025?

As of my last update in October 2023, I cannot provide specific details on advancements that will be highlighted during ACADIA Pharmaceuticals Inc.'s R&D Day on June 25, 2025, as such information is not available in my training data or future forecasts.

How does ACADIA Pharmaceuticals Inc. (ACAD) plan to address the challenges in treating conditions like Prader-Willi syndrome and Alzheimer's disease psychosis?

ACADIA Pharmaceuticals Inc. plans to address challenges in treating conditions like Prader-Willi syndrome and Alzheimer's disease psychosis by advancing its clinical pipeline and leveraging innovative therapies to improve patient outcomes and address unmet medical needs.

Which key opinion leaders (KOL) will participate in ACADIA Pharmaceuticals Inc. (ACAD) R&D Day, and what unique insights can they bring to the discussion?

As of my last update, the specific KOLs participating in ACADIA Pharmaceuticals Inc.'s R&D Day were not disclosed, but attendees typically include experts in neuroscience and psychiatry who can offer valuable insights on advancements in treatments for neurological disorders.

What are the anticipated outcomes or goals for ACADIA Pharmaceuticals Inc. (ACAD) following the R&D Day in terms of investor sentiment and community engagement?

Following the R&D Day, ACADIA Pharmaceuticals Inc. (ACAD) aims to enhance investor sentiment by showcasing innovative pipeline advancements and fostering community engagement through transparent communication about their developmental strategies and potential market impacts.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about this news release.

Get Email and Text Alerts for (NASDAQ:ACAD)

Get Email and Text Alerts for (NASDAQ:ACAD)

News, Short Squeeze, Breakout and More Instantly...

Tags
  • Futures Trading
  • Meetings
  • New York
Share This Post

Market Wire News is a media platform, the information on this page was provided by Business Wire via Quote Media. Read our full disclaimer.

Link your X Account to Market Wire News

When you linking your X Account to Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.


Contact the Author

Stock Information

Get ACAD Alerts

News, Short Squeeze, Breakout and More Instantly...

ACADIA Pharmaceuticals Inc. Company Name:

ACAD Stock Symbol:

NASDAQ Market:

0.45% G/L:

$20.98 Last:

2,047,899 Volume:

$21.96 Open:

$20.98 Close:

ACADIA Pharmaceuticals Inc. Website:

ACADIA Pharmaceuticals Inc. Logo

Ad

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
RECENT ACAD NEWS
  • ACAD - ACAD Price Target Alert: $22.00. Issued by Oppenheimer

    2025-06-26 12:11:45 ET Matthew Hershenhorn from Oppenheimer issued a price target of $22.00 for ACAD on 2025-06-26 11:40:41. The adjusted price target was set to $22.00. At the time of the announcement, ACAD was trading at $22.545. The overall price target consensus is a...

  • ACAD - Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

    Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026....

  • ACAD - Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 187,664 shares of common stock and 89,5...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Important Investor News Alert (NASDAQ: CVKD)

 Logo

  • CVKD - Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

    LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per ev...

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get ACAD Alerts

Get ACAD Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1